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Abstract²We present the development of a high sensitivity, 
label-free, biosensor platform suitable for multiplexed point-of-
care diagnostics. A sensor surface based on a carboxy-terminated  
oligo ethylene-glycol (OEG) self-assembled monolayer (SAM) 
was developed and fully characterised. Optimal conditions for 
antibody immobilisation were found for a buffer pH 
approximately one unit below the pI of the antibody, which 
yielded both higher antibody density on the sensor surface as well 
as higher sensor response to the antigen. At the same time the 
surface showed good resistance to non-specific adsorption of high 
concentrations of proteins. A non-faradaic electrochemical 
impedance spectroscopy biosensor to detect human chorionic 
gonadotropin (hCG) in full serum was demonstrated as a proof 
of concept. By using the phase of the impedance at 100 mHz as 
the sensor response, a linear relationship of the phase shift vs the 
logarithm of hCG concentration was established between 26 fM 
and 0.26 nM with a sensitivity of 0.6 degree per decade, which is 
a significant improvement over current state-of-the-art biosensor 
systems. 
Keywords²Biosensors; Label-free; Impedance Spectroscopy; 
hCG.  
I. INTRODUCTION 
The monitoring of human health through sophisticated in 
vitro diagnostic devices is becoming pivotal in a society 
placing increasing importance on both disease prevention, and 
on stratified and individualised patient care.  However, current 
diagnostic services are under intense pressure to meet these 
emerging healthcare requirements.  In recent years, the 
demand of clinical analysis and monitoring of biological 
samples has been moved from large clinical laboratories to 
point-of-care (POC), i.e. less equipped locations, such as bed-
side care in hospitals, nursing homes, or the patient¶s home 
itself [1]. As a consequence POC tests are usually carried out 
by personnel with little or no specific training [1]. Therefore, 
it is critical for the instrumentation to be self-contained, 
portable and easy-to-use. At the same time, as demands for 
early diagnosis keep rising, the demand for devices that can 
assist with routine check-up procedures and that can be used 
to screen for a multitude of risk-factor indicators is increasing. 
To achieve these goals, the time-to-result and sample 
manipulation procedures need to be reduced and simplified, 
respectively, and innovative diagnostic technologies are 
required to meet these emerging healthcare needs. 
A biosensor is an analytical device where a biological 
event, for example the binding of an analyte, or biomarker, is 
converted into a quantifiable and processable signal [2]. A 
biosensor typically comprises a molecular recognition system, 
also referred to as bioreceptor, that binds specifically to the 
target; and an interface architecture, where a the binding event 
takes place and gives rise to a signal which is picked up by the 
transducer element. The transducer signal is converted to a 
meaningful quantity and displayed for the user to read. 
Many currently available, highly sensitive biosensors rely 
on indirect detection, i.e. by means of a secondary probe or 
label which is introduced in a separate step and binds to the 
receptor-bound target [3]. Two advantages of these systems 
are the potential for signal amplification, e.g. by using 
enzymatic labels [3], and high resistance to non-specific 
binding [1] because the detection of the target relies on two 
independent binding events. However, this type of sensor is 
expensive, as it requires two recognition systems, time-
consuming and makes real-time measurements a significant 
challenge. In addition, it requires multiple steps and hence can 
usually be carried out only by highly trained personnel to 
ensure quality of the analysis and interpretation of the results. 
Biosensors that can detect the target directly (label-free) 
instead offer the possibility of fast analyte detection from a 
sample with no, or very little, sample preparation, enabling 
real-time measurements [1,4]. However, such label-free 
biosensors lack an amplification mechanism and rely on a 
single binding event, and hence require both a high affinity 
and specificity bioreceptor for the target, and a very sensitive 
transducer. Therefore, highly sensitive biosensors with low 
limit of detection are potentially more difficult to achieve. 
A very promising class of label-free biosensors is based on 
electrochemical transducers, and different types of electro-
chemical biosensors have been developed. For example, 
electrochemical impedance biosensors measure the impedance 
of the electrode/solution interface without disrupting the initial 
state of the interface. This is possible by applying a small 
alternating (AC) excitation voltage around a steady bias (DC) 
and measuring the resulting current. Electrochemical 
impedance spectroscopy (EIS) sensors measure the impedance 
of the electrode/solution interface across a frequency range. If 
the impedance of the electrode/solution interface changes 
upon binding of a molecule of interest to a recognition 
element immobilised on the biosensor surface, EIS can be 
used to detect this binding event. In general, the number of 
target molecules bound to the surface-immobilised 
bioreceptors is a very good measure of the concentration of 
the target in solution. Impedance biosensors are intrinsically 
label-free, and once optimised, the same system can be 
employed to detect virtually any target simply by changing the 
bioreceptor attached to the surface.  
  
When a solid electrode is exposed to an electrolyte 
solution, charge is accumulated on the surface, which leads to 
a capacitor-like behaviour of the interface. Therefore, a widely 
employed approach for impedance biosensors is to model the 
sensor/solution interface as a capacitor and to estimate the 
change in capacitance of the sensor upon binding of the target 
to the surface-immobilized receptor, in absence of redox 
probes [4]. In previous work, the total capacitance of the 
sensor/solution interface, Ctot, has been evaluated by 
measuring the transient current at the sensor electrode upon 
application of a potentiostatic step [4]. With this method, 
Berggren et al. developed biosensors for antibodies, antigens, 
proteins, DNA fragments, and heavy metal ions [4]. For 
example, human chorionic gonadotropin (hCG) and 
Interleukine-6 (IL-6) were detected in low molarity phosphate 
buffer (PB) at concentration as little as 15 fM and 0.5 fM, 
respectively [4]. Although only in buffer, this is still one of the 
most sensitive biosensors for hCG reported to date. 
Impedance biosensors can be produced very cost 
effectively by inexpensive mass production technologies. The 
required electrodes are fabricated by means of photo-
lithography or screen printing, and the required 
instrumentation such as lock-in amplifiers is simple and 
readily available.  Provided that adding additional sensors to 
the same device only requires the addition of an extra 
electrode they are ideally suited for multiplexing [5]. 
Furthermore, they are easy to use as they require minimal, or 
no, sample manipulation and the time-to-result is much shorter 
than in labelled biosensor systems. Hence, impedimetric 
biosensors are promising candidate for POC diagnostics. To 
reach this goal it is essential that sensors with high specificity 
and low limits of detection in complex solution such as blood 
serum, are developed. 
In this paper a high sensitivity, label-free, multiplexed, 
electrochemical biosensor platform suitable for POC 
diagnostics is presented. The human hormone hCG was used 
as an exemplar system in a redox-probe-free EIS sensor, and 
by monitoring the phase of the impedance at 100 mHz, a limit 
of detection of 26 fM hCG in full serum is demonstrated. 
II. MATERIALS AND METHODS 
A. Materials 
Acetone, absolute ethanol, methanol, tris, Decon 90, 
platinum wire and Ag/AgCl reference electrode (662-1795) 
were purchased from VWR International Ltd (UK). NaOH, 
glacial acetic acid, HCl, ethanol 200 proof, sodium phosphate 
monobasic monohydrate, sodium phosphate dibasic, sodium 
acetate trihydrate, 2-(N-morpholino)-ethanesulfonic acid 
(MES), hCG and bovine serum albumin (BSA) were sourced 
from Sigma-Aldrich Co (USA). EDC, NHS and ethanolamine-
HCl were purchased from GE Healthcare UK Ltd (UK). Bare 
gold disks for the AUTOLAB ESPRIT surface plasmon 
resonance (SPR) system were sourced from Metrohm Autolab 
BV (Netherlands). Acid capped esa(ethylene glycol)-
undecanethiol (OEG) and monoclonal anti ȕ-hCG antibodies 
(mAb) were supplied from ProChimia Surfaces Sp.zo.o. 
(Poland) and Abbott Laboratories (USA), respectively. 
B. Surface plasmon resonance 
The mAb were immobilised to the surface in different 
coupling buffers, namely 50 mM acetate buffer (AcB) with pH 
4.5 ದ 6 and PB with pH 5.5 ದ 8, as detailed below. The SPR 
disks were cleaned by sonication in 100mM NaOH and 0.1% 
Triton X100 aqueous solution, and in ethanol 200 proof for 10 
minutes each as per manufacturerಬs instructions. The OEG 
SAM was formed by immersion of the substrates for 40 hours 
in 0.5 mM OEG solution of ethanol 200 and 5% acetic acid 
(Fig. 1A) to avoid the formation of dimers and the 
esterification of the COOHs [6]. The substrates were rinsed in 
ethanol, dried under a N2 stream and mounted in the SPR 
instrument. mAbB were bound to the surface using standard 
protocols [7]. After rinsing, the surface was prepared for 
functionalisation by injecting freshly prepared 1:1 mixture of 
400 mM EDC:200 mM NHS in MES buffer pH 5.6 for 10 
minutes (Fig. 1B). The surface was then quickly rinsed with 
MES and the appropriate coupling buffer. Solutions of 0.02 
mg/ml mAb in the respective coupling buffer were injected on 
the surface for 45 minutes (Fig. 1C). The surface was then 
rinsed three times. Ethanolamine 100 mM pH 8 was injected 
for 10 minutes (Fig. 1D) to block any free NHS ester. To 
verify the responsiveness and specificity of the modified 
surface, after stabilisation in PB pH 7.2 the mAB were 
challenged with hCG (Fig. 1E) at different concentrations, and 
BSA was used as negative control. 
C. Electrochemistry 
For electrochemical measurements, Ti/Au (15 nm/80 nm) 
was evaporated by electron-beam evaporation at a base 
pressure of 10-7 mbar on to Si/SiO2 wafers. Prior to 
Fig. 1 Schematic illustration of the functionalisation of the sensor surface. A) SAM formation. B) Activation of COOH groups by means of EDC±NHS. C) 
Covalent binding of antibodies to the SAM. D) Deactivation of residual NHS activated sites by means of ethanolamine. E) Binding of hCG to sensor surface. 
  
evaporation the Si/SiO2 wafers were cleaned by 5 minutes 
sonication in acetone, methanol and DI water. The Au coated 
wafer was cut in devices of appropriate size and cleaned by 
sonication in acetone, ethanol and isopropanol for 10 minutes 
each. The samples were then dried under a N2 stream and 
cleaned by freshly prepared piranha solution (70% H2SO4, 
30% H2O2) for 5 minutes. The samples were sonicated in 
ultrapure water for 10 minutes and in ethanol 200 prior to 
immersion in OEG solution, prepared as mentioned above. 
The sensor surface was functionalised with mAb in AcB pH 
5.5 following the protocol described above. 
The working electrode area (9.13 mm2) was defined by 
means of a square-cut rubber gasket. Cyclic voltammetry was 
performed between ದ0.5 V and 0.6 V in PB (100 mM) 
containing 2 mM of the redox couple (Fe(CN)63-/4-) at 62 
mV/s, for five cycles. Nonfaradaic EIS measurements were 
performed in 100 mM PB (pH 7.2) applying a 10 mV AC 
voltage, with no DC bias, for frequencies between 100 kHz 
and 50 mHz. Faradaic EIS measurements were acquired in 
100 mM PB (pH 7.2) with 2 mM redox couple, applying a DC 
bias of 0.215 V vs reference electrode. 
For calibration of the sensor after antibody immobilisation, 
the devices were incubated in serum for 20 minutes prior to 
nonfaradaic EIS measurement. After each measurement the 
cell was emptied and fresh serum injected. The incubation step 
and measurement was repeated for three more cycles. Serum 
samples spiked with increasing hCG concentration (26 fM to 
0.26 nM) were injected and measured sequentially. The phase 
at 0.1 Hz was extracted from the EIS scans and the average of 
multiple scans was used as the sensor output. 
III. RESULTS AND DISCUSSION 
The sensor devices were characterised by means of both 
SPR and electrochemistry. First, the SAM was characterised 
electrochemically by means of cyclic voltammetry, faradaic 
and nonfaradaic EIS. Electron transfer was found to be 
blocked effectively by the SAM, as evidenced by CV scans 
which showed the absence of redox peaks, and EIS 
measurements performed in presence of redox probes which 
showed the absence of faradaic processes (data not shown). 
This is indicative of the formation of a well packed, 
electrically blocking, SAM [8]. 
Second, the immobilisation process of the antibodies was 
characterised by means of SPR to establish the adsorption 
conditions, i.e. coupling buffer pH, that maximise the sensor 
response. It was found that for buffer pH  5.5 the amount of 
adsorbed mAbB was equal to 4.1 ± 0.4 ng/mm2, which 
indicates full coverage, provided that the theoretically 
calculated values of maximum surface coverage is 3.77 
ng/mm2 [9], when the antibodies are considered to be 
homogeneous spheres, and 5.5 ng/mm2, when they are 
assumed to be uniformly oriented and in their most compact 
configuration. In contrast, adsorption density was negligible 
(0.45 ng/mm2) for pH  6. This can be explained by 
considering the electrostatic forces between the mAb and the 
surface [9]. At pH smaller than the isoelectric point (pI) the 
mAb has a net positive charge. The mAb pI is § 6.5, hence at 
pH  5.5 the mAb are positively charged while the residual 
carboxylic acids on the sensor surface are negatively charged. 
This results in an electrostatic attraction that drives the 
adsorption of antibodies to the surface so that covalent binding 
can occur. It was found that for AcB pH 5.5, i.e. pH § pI ± 1, 
the sensor yields both the highest adsorption of mAb and at 
the same time the highest response of the sensor to hCG. 
The specificity of the sensor to hCG and the resistance to 
nonspecific binding of the OEG SAM [10] was verified by 
means of SPR using BSA as negative control. BSA was 
chosen as it is known to bind non-specifically to surfaces [3] 
and serum albumin is present in high concentration in blood 
serum (41-45 mg/ml). Therefore, investigating the selectivity 
of the sensor to BSA is important to gain insight into the 
sensor¶s behaviour when exposed to complex solutions. The 
response of the sensor to 135 nM hCG, established over three 
separate experiments under the same conditions, is equal to 75 
± 8 m° (0.62 ± 0.06 ng/mm2) compared to the very small 
response to the same concentration of BSA (Fig. 2). 
Subsequently, the immobilisation of mAb in AcB pH 5.5 
was also characterised by non-faradaic EIS. A decrease in the 
impedance phase at low frequencies is noted in the spectra 
after mAbs are adsorbed on the surface. A decrease of the 
phase at 100 mHz measured in PB 100 mM pH 7.2 equal to 
2.4° ± 0.8° was observed across six samples (data not shown).  
The sensor/solution interface can be described by a 
network of electronic circuit elements with overall impedance 
equivalent to that of the interface. The phase of the impedance 
is close to ದ90° for a highly insulating, defect-free, 
sensor/solution interface, and it increases towards zero for a 
non-blocking interface [12,13]. Therefore, the observed 
decrease of the phase towards ದ90°, indicates a decrease in 
leakage of the coating layer [12,13], suggesting that the 
antibodies form a layer that further hinders the access to the 
gold surface by currents of ions.  
Fresh sensors were then made and characterised by means 
of EIS in horse serum (Fig. 3), to test both the selectivity of 
the sensor for hCG, and the behaviour of the sensor in 
clinically relevant samples. Fig. 3 shows the phase spectra 
obtained by means of EIS in blank and spiked serum. 
Although it was possible to fit the EIS spectra with an 
Sponsors: BBSRC and Abbott Laboratories 
Fig. 2  Example SPR sensogram of (A) functionalisation of surface with 
mAb in AcB pH 5.5 by NHS-EDC chemistry and (B) surface response to   
hCG (black line) and BSA (red line), both at a concentration of 135 nM in 
100 mM phosphate buffer pH 7.2. The arrow indicates the time of injection. 
  
equivalent circuit (Fig. 3) the simplest circuit that was found 
to fit the data accurately comprised five circuit elements with 
seven free parameters. 
Owing to the complexity of the interpretation of this 
equivalent circuit system, the calibration curve of the sensor 
(Fig. 4) was obtained by monitoring the shift in phase, ¨ĳ, at a 
single frequency of 100 mHz. This frequency was chosen as 
representative of the phase of the system at low frequencies 
[12], where the signal to noise ratio is maximised. The phase-
shift ¨ĳ increases linearly with the logarithm of hCG 
concentration over 5 decades, showing a sensitivity of 0.6° ± 
0.1° per decade for hCG in full horse serum. The curve shown 
is the average over 4 measurements and the error bars indicate 
the standard deviations. The lowest concentration detected for 
hCG in serum was 26 fM. We note that the detection limit 
obtained in full unprocessed serum for this sensor is 
comparable to the one obtained for the capacitive sensor 
discussed in the introduction, but the latter used in 10 mM PB 
[4], which is significantly less challenging than serum. 
Considering that the sensor shows no response to blank 
injections of serum (Fig. 4, left), i.e. serum not spiked with 
hCG, helps in correlating the response of the sensor to the 
concentration of hCG when the sensor surface is exposed to 
spiked buffer. Moreover, on the same graph, the response of a 
sensor modified with anti-mouse antibodies to both blank and 
hCG-spiked serum is reported as negative control.  
The phase of the impedance is independent of the surface 
area of the sensor, in contrast to other frequently employed 
quantities such as the magnitude of the impedance, the charge 
transfer resistance, or the capacitance of the layer. This is a 
highly desirable characteristic for a biosensor as it makes it 
robust against manufacturing tolerances typical for 
miniaturisation and therefore multiplexing.  
IV. CONCLUSIONS 
A label-free EIS biosensors with high sensitivity for the 
model target hCG in full serum was demonstrated. Optimal 
binding conditions for the capture antibodies to the sensor 
surface were established by SPR and found for binding buffers 
with pH § pI ± 1. The phase shift of the impedance at a fixed 
frequency of 100 mHz was found to be a good measure for the 
amount of binding observed, and the EIS sensor was 
calibrated for a range of different hCG concentrations in horse 
serum. A linear relationship of the phase shift vs the logarithm 
of hCG concentration was found between 26 fM and 0.26 nM 
with a sensitivity of 0.6 degree per decade. The sensor did not 
show any response to consecutive injections of serum, and 
sensors modified with antibodies not specific to hCG showed 
no response. Moreover the phase at a single frequency is an 
easy-to-measure physical quantity that does not require post-
processing or fitting of complex equivalent circuits. 
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Fig. 4  Impedance phase-shift at 100 mHz (ǻ˳) measured by means of EIS 
for non-spiked serum injections (left) and spiked serum with increasing 
concentration of hCG (right), for sensor surface functionalised with anti-
hCG monoclonal antibody (red dots) and anti-mouse antibodies (blue x). 
Error bars represent ±SD between samples. The line represents a linear fit 
of the phase shift vs log[hCG] for hCG response from 26 fM to 0.26 nM. 
Fig. 3 Typical Impedance phase (˳) spectra recorded by means of EIS 
(symbols) for successive non-spiked serum injections and increasing 
concentration of hCG between 26 fM and 0.26 nM in serum. Each spectrum 
was obtained after 20 minutes of incubation. Lines represent fits to EIS 
measurements according to the equivalent circuit presented in the inset. 
